ATE371738T1 - Mittel und verfahren zur diagnose und behandlung affektiver störungen - Google Patents
Mittel und verfahren zur diagnose und behandlung affektiver störungenInfo
- Publication number
- ATE371738T1 ATE371738T1 AT04009160T AT04009160T ATE371738T1 AT E371738 T1 ATE371738 T1 AT E371738T1 AT 04009160 T AT04009160 T AT 04009160T AT 04009160 T AT04009160 T AT 04009160T AT E371738 T1 ATE371738 T1 AT E371738T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- acid molecules
- present
- methods
- relates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000019022 Mood disease Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 9
- 102000039446 nucleic acids Human genes 0.000 abstract 9
- 150000007523 nucleic acids Chemical class 0.000 abstract 9
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108091023037 Aptamer Proteins 0.000 abstract 2
- 108090000862 Ion Channels Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 108020003589 5' Untranslated Regions Proteins 0.000 abstract 1
- 208000017194 Affective disease Diseases 0.000 abstract 1
- 108091092195 Intron Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009452 underexpressoin Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03008753 | 2003-04-17 | ||
| EP03019626 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE371738T1 true ATE371738T1 (de) | 2007-09-15 |
Family
ID=33300969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04009160T ATE371738T1 (de) | 2003-04-17 | 2004-04-16 | Mittel und verfahren zur diagnose und behandlung affektiver störungen |
| AT04018640T ATE365798T1 (de) | 2003-04-17 | 2004-04-16 | Mittel und verfahren zur diagnose und behandlung affektiver störungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04018640T ATE365798T1 (de) | 2003-04-17 | 2004-04-16 | Mittel und verfahren zur diagnose und behandlung affektiver störungen |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20060110385A1 (de) |
| EP (2) | EP1473367B1 (de) |
| JP (2) | JP2006523648A (de) |
| AT (2) | ATE371738T1 (de) |
| CA (1) | CA2522985A1 (de) |
| DE (2) | DE602004008528T2 (de) |
| DK (2) | DK1469072T3 (de) |
| ES (2) | ES2286543T3 (de) |
| MX (1) | MXPA05011008A (de) |
| PL (2) | PL1473367T3 (de) |
| PT (2) | PT1469072E (de) |
| WO (1) | WO2004092384A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1961767B1 (de) | 2001-01-17 | 2012-03-07 | Biosceptre International Limited | Diagnose und Behandlung von Karzinomen und anderen Leiden |
| WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| US8124730B1 (en) | 2004-04-02 | 2012-02-28 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v |
| RU2410430C2 (ru) * | 2004-08-31 | 2011-01-27 | Силентис С.А.У. | Способы и композиции для ингибирования экспрессии рецептора p2х7 |
| JP2008542385A (ja) * | 2005-05-31 | 2008-11-27 | ダスカ サイエンティフィック コーポレーション | 神経損傷の抑制 |
| WO2007115095A2 (en) * | 2006-03-29 | 2007-10-11 | The Trustees Of Columbia University In The City Ofnew York | Systems and methods for using molecular networks in genetic linkage analysis of complex traits |
| WO2007115192A2 (en) * | 2006-03-31 | 2007-10-11 | Abbott Laboratories | P2x7 antagonists to treat affective disorders |
| JP2010505426A (ja) | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ |
| US20100036101A1 (en) * | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| EP1938801A1 (de) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| WO2009019503A2 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | P2x7 antagonists for use in the treatment of mood disorders |
| CA2737126C (en) * | 2007-09-14 | 2018-05-01 | Biosceptre International Limited | Novel p2x7 epitopes |
| JP5624885B2 (ja) | 2007-09-14 | 2014-11-12 | バイオセプター・インターナショナル・リミテッド | 細胞外体液中のプリン作動性（ｐ２ｘ）受容体 |
| WO2009045381A1 (en) * | 2007-10-04 | 2009-04-09 | Merck & Co., Inc. | N-substituted oxindoline derivatives as calcium channel blockers |
| BRPI0915367B8 (pt) | 2008-07-04 | 2021-05-25 | Biosceptre International Ltd | peptídeo anti-p2x7 |
| JP5936067B2 (ja) | 2009-08-20 | 2016-06-15 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 抗ｐ２ｘ７受容体抗体およびその断片 |
| US8835609B2 (en) | 2009-12-24 | 2014-09-16 | Biosceptre International Limited | Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof |
| EP2613808B1 (de) | 2010-09-10 | 2017-11-08 | Biosceptre (Aust) Pty Ltd | Haustier krebst therapien mit einem anti p2x7 antikörper |
| AU2012278921B2 (en) | 2011-07-01 | 2016-11-10 | Biosceptre International Limited | Combination therapy |
| WO2014182601A1 (en) | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| JP6728657B2 (ja) * | 2015-12-04 | 2020-07-22 | 東洋紡株式会社 | 核酸増幅法 |
| WO2017165423A1 (en) * | 2016-03-21 | 2017-09-28 | Indiana University Research & Technology Corporation | Drugs, pharmacogenomics and biomarkers for active longevity |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
| CN115381950B (zh) * | 2022-09-06 | 2023-08-18 | 天津医科大学总医院 | Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用 |
| WO2024208433A1 (en) | 2023-04-06 | 2024-10-10 | Biofrontera Bioscience Gmbh | Nanoemulsion without propylene glycol |
| WO2024208434A1 (en) | 2023-04-06 | 2024-10-10 | Biofrontera Bioscience Gmbh | Pressurized nanoemulsion |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214581B1 (en) * | 1998-01-16 | 2001-04-10 | Abbott Laboratories | Nucleic acids encoding a functional human purinoreceptor P2X3 and P2X6, and methods of production and use thereof |
| WO1999055901A2 (en) * | 1998-04-30 | 1999-11-04 | Abbott Laboratories | Screening assay for identifying human purinoreceptor ligands |
| JP2000095695A (ja) * | 1998-07-23 | 2000-04-04 | Nippon Koutai Kenkyusho:Kk | 精神分裂病治療薬 |
| BR0008477A (pt) * | 1999-02-24 | 2002-01-22 | Univ Cincinnati | Método para tratar um distúrbio de controle do impulso |
| WO2001044509A1 (en) | 1999-12-16 | 2001-06-21 | Center For Advanced Science And Technology Incubation, Ltd. | Method of detecting target base sequence |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| AU2001233955A1 (en) * | 2000-02-24 | 2001-09-03 | Oxford Glycosciences (Uk) Limited | Diagnosis and treatment of bipolar affective disorder |
| JP2002330787A (ja) * | 2000-10-21 | 2002-11-19 | Astrazeneca Ab | 化学物質 |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| BR0215288A (pt) * | 2001-12-21 | 2004-12-21 | King Phamaceuticals Res & Dev | Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente |
| US20040029841A1 (en) * | 2002-04-18 | 2004-02-12 | Renshaw Perry F. | Purinergic antagonists for treating depression |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
| US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
| FR2867784B1 (fr) | 2004-03-17 | 2006-06-09 | Commissariat Energie Atomique | Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications |
-
2004
- 2004-04-16 WO PCT/EP2004/004076 patent/WO2004092384A2/en not_active Ceased
- 2004-04-16 ES ES04018640T patent/ES2286543T3/es not_active Expired - Lifetime
- 2004-04-16 PL PL04018640T patent/PL1473367T3/pl unknown
- 2004-04-16 DK DK04009160T patent/DK1469072T3/da active
- 2004-04-16 ES ES04009160T patent/ES2293114T3/es not_active Expired - Lifetime
- 2004-04-16 EP EP04018640A patent/EP1473367B1/de not_active Expired - Lifetime
- 2004-04-16 PT PT04009160T patent/PT1469072E/pt unknown
- 2004-04-16 PT PT04018640T patent/PT1473367E/pt unknown
- 2004-04-16 AT AT04009160T patent/ATE371738T1/de not_active IP Right Cessation
- 2004-04-16 EP EP04009160A patent/EP1469072B1/de not_active Expired - Lifetime
- 2004-04-16 AT AT04018640T patent/ATE365798T1/de not_active IP Right Cessation
- 2004-04-16 JP JP2006505172A patent/JP2006523648A/ja not_active Ceased
- 2004-04-16 DE DE602004008528T patent/DE602004008528T2/de not_active Expired - Lifetime
- 2004-04-16 DE DE602004007184T patent/DE602004007184T2/de not_active Expired - Lifetime
- 2004-04-16 US US10/553,298 patent/US20060110385A1/en not_active Abandoned
- 2004-04-16 DK DK04018640T patent/DK1473367T3/da active
- 2004-04-16 US US10/825,593 patent/US20050147604A1/en not_active Abandoned
- 2004-04-16 PL PL04009160T patent/PL1469072T3/pl unknown
- 2004-04-16 CA CA002522985A patent/CA2522985A1/en not_active Abandoned
- 2004-04-16 MX MXPA05011008A patent/MXPA05011008A/es active IP Right Grant
-
2007
- 2007-05-16 US US11/749,645 patent/US7767398B2/en not_active Expired - Fee Related
- 2007-05-16 US US11/749,629 patent/US20080200411A1/en not_active Abandoned
-
2009
- 2009-08-27 JP JP2009196458A patent/JP2010011855A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL1473367T3 (pl) | 2007-11-30 |
| EP1469072A3 (de) | 2004-11-24 |
| JP2006523648A (ja) | 2006-10-19 |
| US7767398B2 (en) | 2010-08-03 |
| DE602004008528D1 (de) | 2007-10-11 |
| MXPA05011008A (es) | 2006-03-08 |
| PT1473367E (pt) | 2007-09-10 |
| DE602004007184T2 (de) | 2008-02-28 |
| EP1469072A2 (de) | 2004-10-20 |
| ES2293114T3 (es) | 2008-03-16 |
| EP1473367A1 (de) | 2004-11-03 |
| EP1469072B1 (de) | 2007-08-29 |
| DK1473367T3 (da) | 2007-10-01 |
| US20080057504A1 (en) | 2008-03-06 |
| JP2010011855A (ja) | 2010-01-21 |
| CA2522985A1 (en) | 2004-10-28 |
| US20060110385A1 (en) | 2006-05-25 |
| WO2004092384A3 (en) | 2005-06-02 |
| PL1469072T3 (pl) | 2008-03-31 |
| EP1473367B1 (de) | 2007-06-27 |
| ATE365798T1 (de) | 2007-07-15 |
| US20080200411A1 (en) | 2008-08-21 |
| DE602004008528T2 (de) | 2008-05-21 |
| PT1469072E (pt) | 2007-10-29 |
| WO2004092384A2 (en) | 2004-10-28 |
| DK1469072T3 (da) | 2008-01-07 |
| ES2286543T3 (es) | 2007-12-01 |
| US20050147604A1 (en) | 2005-07-07 |
| DE602004007184D1 (de) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE365798T1 (de) | Mittel und verfahren zur diagnose und behandlung affektiver störungen | |
| ATE551350T1 (de) | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration | |
| JP2008538238A5 (de) | ||
| EP1581656A4 (de) | MODULATION DER EXPRESSION VON HIF1a UND HIF2a | |
| DE602005019064D1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| AU7026601A (en) | Thymic stromal lymphopoietin receptor molecules and uses thereof | |
| WO2010011283A3 (en) | Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases | |
| EP1987165A4 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
| ATE378423T1 (de) | Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie | |
| WO2007059064A3 (en) | Fgf2-related methods for diagnosing and treating depression | |
| ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
| HK1042523A1 (zh) | 青光眼和有關疾病的核酸、工具和其診斷、預後和治療的方法 | |
| WO2003087408A3 (en) | Schizophrenia associated genes | |
| DE60018964D1 (de) | Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen | |
| ATE460673T1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
| ATE522625T1 (de) | Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker | |
| Araya et al. | Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model | |
| Hasselmann | Generation and application of a chimeric model to examine human microglia responses to amyloid pathology | |
| DE60140934D1 (de) | Polymorphismen des humanen cyp2b6 gens und deren verwendung in diagnostischen und therapeutischen anwendungen | |
| WO2007039232A3 (en) | Means and methods for diagnosing atgl related disorders | |
| DE602004024300D1 (de) | Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs | |
| Shireby | Regulatory genomic consequences of polygenic risk burden for Alzheimer’s disease | |
| SE9902489D0 (sv) | Mutated Nurr1 gene | |
| Sheerin | The Use of Next Generation Sequencing Technologies to Dissect the Aetiologies of Parkinson’s disease and Dystonia | |
| WO2005114216A3 (en) | Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1469072 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |